BP vs BTE

BP's Advanced Deterministic Scorecard shows a Piotroski F-Score of 6/9, indicating stable financial health, but the absence of an Altman Z-Score limits distress risk assessment. The stock trades at a significant premium to its Graham Number ($7.35) and even the growth-based intrinsic value ($18.88), currently priced at $36.53, driven by high forward earnings expectations. While profitability metrics and dividend yield are attractive, elevated valuation multiples, inconsistent earnings surprises, and a dangerously high payout ratio of 315% raise sustainability concerns. Analysts recommend a 'buy' with a target of $38.73, supported by strong insider sentiment, though no insider transactions have occurred recently.

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a concerning lack of Altman Z-Score data, which raises transparency and solvency concerns. Despite trading below its Graham Number of $4.22 at $3.32, the stock shows deteriorating fundamentals, including sharply negative earnings and revenue growth (YoY: -82.6% and -12.3%, respectively), weak profitability trends, and a deteriorating technical trend (10/100). While the dividend appears sustainable with a 32% payout ratio, the current ratio of 0.58 signals near-term liquidity pressure. The company's inconsistent earnings performance, with frequent large misses and volatility in surprises, undermines confidence in its operational predictability.